MEDP vs PEN
Medpace vs Penumbra, Inc. — AI-powered side-by-side comparison
VS
PEN
Penumbra, Inc.
67
Buy
| Metric | MEDP | PEN |
|---|
| AI Score |
67
|
67
|
| Price |
$578.86
|
$327.06
|
| P/E Ratio |
33.46×
|
79.89×
|
| ROE |
98.3%
|
12.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.8%
|
67.8%
|
| Debt / Equity |
0.28×
|
0.14×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
48.8
|
82.5
|
| Beta |
1.151
|
0.701
|
| Expected Upside |
+7.1%
|
+6.0%
|
AI Committee View
Current Innellis committee reasoning for MEDP versus PEN.
The committee scores are tied.
MEDP and PEN both score 67/100.
MEDP Committee View
67% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is p/e of 33.1 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 33.1 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
PEN Committee View
67% agreement
6 analysts
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+1.00 across 2 articles, 14d). Value Analyst remains cautious — p/e of 80.0 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 80.0 is expensive by classic value standards — Value
- Price-to-book of 8.5x prices in significant intangible value — Value
- 2 consecutive earnings misses -- execution concerns — Growth